Certolizumab Pegol Is Associated With Long-Term Improvements in Patient-Reported Outcomes in Psoriatic Arthritis: 4-Year Outcomes From the Rapid-Psa Study
Value in Health- United Kingdom
doi 10.1016/j.jval.2016.09.1426
Full Text
Abstract
Available in
Date
November 1, 2016
Authors
Publisher
Elsevier BV